ArticleDrug and alcohol review2026
Experiences and Predictors of Real-Time Prescription Drug Monitoring Program Use Among Australian Community Pharmacists: A Nationwide Study.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPrescription drug monitoring programs (PDMP) are a key supply-side policy aimed at reducing medication-related harms, which have been implemented in all Australian states and territories; however, experiences have not been explored nationally among community pharmacists. The objectives of this study were to investigate PDMP use among Australian community pharmacists, including frequency of use, reasons for and barriers to use.
methodsAn anonymous online survey collected data on: (i) the pharmacist (i.e., gender, years of pharmacy experience, PDMP training) and the pharmacy (i.e., location, pharmacy type, average number of daily prescriptions received); and (ii) PDMP use (i.e., frequency of use, reasons for checking PDMP, frequency of barriers experienced). Logistic regression was used to explore the factors associated with frequent PDMP use.
resultsAmong a sample of 730 community pharmacists, regular ('all the time') PDMP use was more common in mandated (74.1%), compared to non-mandated (45.7%) states/territories (p < 0.001). Few pharmacists reported experiencing barriers 'all the time' in mandated (4.0%) and non-mandated (4.8%) states/territories. Pharmacists working in mandated states/territories (aOR: 3.64; 95% CI 2.60-5.09), capital cities (aOR: 1.90; 95% CI 1.34-2.70) and pharmacies that are part of chain/banner group (aOR: 1.49; 95% CI 1.04-2.13) were more likely to use PDMP 'all the time', compared with those with less frequent use. DISCUSSION AND
conclusionsAustralian community pharmacists demonstrate variations in the frequency and reasons for PDMP use. Concerted efforts through education and practise-level interventions are needed to encourage PDMP use, particularly in non-mandated states and territories, independent pharmacies, and those working outside capital cities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.